MERGERS AND ACQUISITIONS Wilson Wolf Corp., New Brighton, has entered into an asset purchase agreement with Wheaton under which Wheaton has acquired the Cellline Bioreactor Flask product line and will commercialize other Wilson Wolf technology directed at the production of cell-secreted proteins such as antibody and recombinant protein.
about the writer
The state will lose about $18 million in federal funding as the Trump administration terminates two pandemic-era programs.
